Anti-ASNA1

ASNA1 (also known as TRC40) is a highly conserved ATPase involved in efflux of arsenite and antimonite. Reduced ASNA1 expression is associated with significant inhibition of cell growth,increased apoptosis and increased sensitivity to cisplatin and arsenite.Thus ASNA1 is proposed to be a target to overcome resistance to cancer chemotherapy. In addition,ASNA1 has been identified as an ER targeting factor for tail-anchored proteins in the posttranslational membrane insertion pathway. Protein function: ATPase required for the post-translational delivery of tail- anchored (TA) proteins to the endoplasmic reticulum. Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then targets to the endoplasmic reticulum by membrane-bound receptors, where the tail-anchored protein is released for insertion. This process is regulated by ATP binding and hydrolysis. ATP binding drives the homodimer towards the closed dimer state, facilitating recognition of newly synthesized TA membrane proteins. ATP hydrolysis is required for insertion. Subsequently, the homodimer reverts towards the open dimer state, lowering its affinity for the membrane-bound receptor, and returning it to the cytosol to initiate a new round of targeting. May be involved in insulin signaling. [The UniProt Consortium]